Ming Xu, Radiopharmaceuticals Portfolio Lead at Bayer, shared on LinkedIn:
“I’m happy to share that I’m starting a new role as Radiopharmaceuticals Portfolio Lead at Bayer!
Radiopharmaceuticals represent one of the most promising frontiers in oncology, combining the precision of targeted delivery with the power of radionuclides to address significant unmet medical needs for cancer patients.
I am honored to have the opportunity to help shape and advance a portfolio in this rapidly evolving field. I look forward to partnering with talented colleagues and collaborators across Research and Development, Product Supply, and Commercial functions to advance innovative therapies to patients.
Many thanks to the mentors, collaborators, and teams who have supported and inspired me throughout this journey. I am excited for what lies ahead.”
You might be interested in:
Japan Approves Bayer’s Sevabertinib for HER2-Mutant NSCLC Across All Lines of Therapy
